false false 2019-12-31 2019 FY FY 0001578845 0001620602 --12-31 --12-31 Large Accelerated Filer Non-accelerated Filer P3Y P1Y After one year P1Y P1Y 1 P5Y 1 P3Y P3Y P3Y P3Y P4Y P3Y P10Y P15Y P10Y P10Y P50Y P20Y P6Y8M12D P3Y8M12D P6Y7M6D P6Y10M24D P7Y1M6D P5Y1M6D P8Y9M18D P2Y9M18D P6Y3M18D P7Y P7Y P7Y 0.017 0.022 0.235 0.264 0.019 0.022 0.020 0.026 0.029 0.023 P1Y7M6D P1Y4M24D 0 1600000 3300000 2013 2014 2015 2016 2010 2011 2012 2013 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014 2015-03-17 P4Y4M24D P3Y10M24D P4Y4M24D P3Y10M24D 0001578845 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-01-01 2019-12-31 0001578845 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001578845 agn:FloatingRateNotesDue2020Member 2019-01-01 2019-12-31 0001578845 agn:ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember 2019-01-01 2019-12-31 0001578845 agn:OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember 2019-01-01 2019-12-31 0001578845 agn:OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-12-31 0001578845 agn:TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember 2019-01-01 2019-12-31 0001578845 agn:TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember 2019-01-01 2019-12-31 xbrli:shares 0001578845 2020-02-12 iso4217:USD 0001578845 2019-06-30 0001578845 2019-12-31 0001578845 2018-12-31 iso4217:USD xbrli:shares 0001578845 2018-01-01 2018-12-31 0001578845 2017-01-01 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-12-31 0001578845 2017-12-31 0001578845 2016-12-31 0001578845 agn:ZeltiqMember 2017-01-01 2017-12-31 0001578845 us-gaap:CommonStockMember 2016-12-31 0001578845 us-gaap:PreferredStockMember 2016-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001578845 us-gaap:RetainedEarningsMember 2016-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2016-12-31 0001578845 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001578845 agn:ZeltiqAestheticsIncMember us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001578845 agn:ZeltiqAestheticsIncMember 2017-01-01 2017-12-31 0001578845 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001578845 us-gaap:CommonStockMember 2017-12-31 0001578845 us-gaap:PreferredStockMember 2017-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001578845 us-gaap:RetainedEarningsMember 2017-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2017-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001578845 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001578845 us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001578845 us-gaap:CommonStockMember 2018-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001578845 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001578845 us-gaap:CommonStockMember 2019-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember 2016-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2016-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2016-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2016-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 agn:GlobalGenericsMember 2019-01-01 2019-12-31 0001578845 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2019-01-01 2019-12-31 0001578845 agn:ZeltiqAestheticsIncMember 2019-01-01 2019-12-31 0001578845 agn:LifeCellCorporationMember 2019-01-01 2019-12-31 0001578845 us-gaap:RevenueCommissionersIrelandMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember agn:RevenueCommissionersBermudaMember 2019-01-01 2019-12-31 agn:Country 0001578845 agn:AbbVieIncMember 2019-06-25 0001578845 agn:AbbVieIncMember 2019-06-24 2019-06-25 0001578845 agn:AbbVieIncMember 2019-10-25 0001578845 agn:AbbVieIncMember 2019-10-25 2019-10-25 agn:Ratio 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2013-09-30 2013-10-01 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2018-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0001578845 us-gaap:RealEstateMember 2019-01-01 0001578845 agn:FleetMember 2019-01-01 0001578845 agn:OtherMember 2019-01-01 0001578845 2019-01-01 0001578845 us-gaap:AccountingStandardsUpdate201602Member srt:RestatementAdjustmentMember 2019-01-02 2019-01-02 0001578845 agn:ComputerHardwareAndSoftwareMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:ComputerHardwareAndSoftwareMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 agn:ResearchAndLaboratoryEquipmentMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:ResearchAndLaboratoryEquipmentMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 agn:BuildingBuildingImprovementsAndLeaseholdImprovementsMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:BuildingBuildingImprovementsAndLeaseholdImprovementsMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:TransportationEquipmentMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 us-gaap:TransportationEquipmentMember srt:MaximumMember 2019-01-01 2019-12-31 xbrli:pure 0001578845 agn:ChargebacksMember 2017-12-31 0001578845 agn:RebatesMember 2017-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2017-12-31 0001578845 agn:CashDiscountsMember 2017-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2017-12-31 0001578845 agn:ChargebacksMember 2018-01-01 2018-12-31 0001578845 agn:RebatesMember 2018-01-01 2018-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2018-01-01 2018-12-31 0001578845 agn:CashDiscountsMember 2018-01-01 2018-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2018-01-01 2018-12-31 0001578845 agn:ChargebacksMember 2018-12-31 0001578845 agn:RebatesMember 2018-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2018-12-31 0001578845 agn:CashDiscountsMember 2018-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2018-12-31 0001578845 agn:ChargebacksMember 2019-01-01 2019-12-31 0001578845 agn:RebatesMember 2019-01-01 2019-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-01-01 2019-12-31 0001578845 agn:CashDiscountsMember 2019-01-01 2019-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-01-01 2019-12-31 0001578845 agn:ChargebacksMember 2019-12-31 0001578845 agn:RebatesMember 2019-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-12-31 0001578845 agn:CashDiscountsMember 2019-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-12-31 0001578845 us-gaap:ProductMember 2019-01-01 2019-12-31 0001578845 us-gaap:ProductMember 2018-01-01 2018-12-31 0001578845 us-gaap:ProductMember 2017-01-01 2017-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-12-31 0001578845 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-12-31 0001578845 2018-01-02 2018-01-02 0001578845 agn:StockAwardsMember 2019-01-01 2019-12-31 0001578845 agn:StockAwardsMember 2018-01-01 2018-12-31 0001578845 agn:StockAwardsMember 2017-01-01 2017-12-31 0001578845 agn:EnvyMedicalIncMember 2019-03-26 2019-03-26 0001578845 agn:EnvyMedicalIncMember 2019-03-26 0001578845 agn:BontiIncMember 2018-10-24 2018-10-24 0001578845 srt:MaximumMember agn:BontiIncMember 2018-10-24 0001578845 agn:BontiIncMember 2018-01-01 2018-12-31 0001578845 agn:ElastagenPtyLimitedMember 2018-04-06 2018-04-06 0001578845 srt:MaximumMember agn:ElastagenPtyLimitedMember 2018-04-06 0001578845 agn:ReprosTherapeuticsIncorporationMember 2018-01-30 2018-01-31 0001578845 agn:AclarisTherapeuticsIncMember 2018-11-30 0001578845 us-gaap:AssetManagementIncomeMember agn:AclarisTherapeuticsIncMember 2018-11-30 2018-11-30 agn:Product 0001578845 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2018-09-20 2018-09-20 0001578845 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2018-09-20 0001578845 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember srt:MaximumMember 2018-09-20 0001578845 agn:KellerMedicalIncMember 2017-06-22 2017-06-23 0001578845 agn:ZeltiqAestheticsIncMember 2017-04-27 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember srt:MinimumMember agn:IndefiniteInProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember srt:MaximumMember agn:IndefiniteInProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-04-28 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:ZeltiqAestheticsIncMember agn:ConsumablesMember 2017-04-28 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:ZeltiqAestheticsIncMember agn:SystemMember 2017-04-28 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:ZeltiqAestheticsIncMember 2017-04-28 0001578845 us-gaap:CustomerRelationshipsMember agn:ZeltiqAestheticsIncMember 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:ConsumablesMember 2017-04-27 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:SystemMember 2017-04-27 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember us-gaap:CustomerRelationshipsMember 2017-04-27 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember agn:USSpecializedTherapeuticsMember 2017-04-28 0001578845 agn:ZeltiqAestheticsIncMember agn:InternationalMember 2017-04-28 0001578845 agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 agn:LifeCellCorporationMember 2017-02-28 0001578845 agn:CurrentlyMarketedProductMember agn:LifeCellCorporationMember 2017-02-28 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:LifeCellCorporationMember 2017-02-28 0001578845 agn:LifeCellCorporationMember agn:IndefiniteInProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:AllodermMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:RevolveMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:StratticeMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:ArtiaMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember agn:OtherProductsMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:MarketingRelatedIntangibleAssetsMember 2017-02-01 0001578845 agn:LifeCellCorporationMember us-gaap:CustomerRelationshipsMember 2017-02-01 0001578845 agn:LifeCellCorporationMember 2017-02-01 0001578845 agn:LifeCellCorporationMember agn:OtherProductsMember agn:IndefiniteInProcessResearchAndDevelopmentMember 2017-02-01 0001578845 agn:LifeCellCorporationMember agn:IndefiniteInProcessResearchAndDevelopmentMember 2017-02-01 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:AllodermMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:RevolveMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:StratticeMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:ArtiaMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 us-gaap:MarketingRelatedIntangibleAssetsMember agn:OtherProductsMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 us-gaap:CustomerRelationshipsMember agn:LifeCellCorporationMember 2017-01-31 2017-02-01 0001578845 agn:USSpecializedTherapeuticsMember agn:LifeCellCorporationMember 2017-02-01 0001578845 agn:LyndraIncMember agn:UltraLongActingOralProductMember 2017-07-31 2017-07-31 0001578845 agn:LyndraIncMember agn:UltraLongActingOralProductMember 2017-01-01 2017-12-31 0001578845 agn:LyndraIncMember agn:UltraLongActingOralProductMember srt:MaximumMember 2018-01-01 2018-12-31 0001578845 agn:EditasMedicineMember agn:EyeCareMember 2017-03-14 2017-03-14 0001578845 agn:EditasMedicineMember agn:EyeCareMember 2017-01-01 2017-12-31 0001578845 agn:EditasMedicineMember 2018-01-01 2018-12-31 0001578845 agn:AssemblyBiosciencesIncMember 2017-01-08 2017-01-09 0001578845 agn:AssemblyBiosciencesIncMember 2017-01-01 2017-12-31 0001578845 agn:AssemblyBiosciencesIncMember srt:MaximumMember 2017-01-01 2017-12-31 0001578845 agn:LysosomalTherapeuticsIncMember 2017-01-08 2017-01-09 0001578845 agn:LysosomalTherapeuticsIncMember agn:OptionRightMember 2017-01-08 2017-01-09 0001578845 agn:LysosomalTherapeuticsIncMember 2017-01-01 2017-12-31 0001578845 agn:SaintRegisMohawkTribeMember 2017-09-07 2017-09-08 0001578845 agn:SaintRegisMohawkTribeMember 2017-09-08 0001578845 agn:SaintRegisMohawkTribeMember us-gaap:LicenseMember 2017-01-01 2017-12-31 0001578845 agn:SaintRegisMohawkTribeMember 2019-12-31 0001578845 agn:SaintRegisMohawkTribeMember 2018-12-31 0001578845 2019-01-01 2019-06-30 0001578845 agn:IronwoodCollaborationAgreementMember 2007-09-01 2007-09-30 0001578845 agn:LinzessMember 2018-01-01 2018-12-31 0001578845 agn:AmgenIncMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-12-31 0001578845 agn:AmgenIncMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:AndaDistributionMember 2016-10-01 2016-10-03 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:AndaDistributionMember 2016-10-03 0001578845 agn:GenericsBusinessAndAndaDistributionBusinessMember 2016-01-01 2016-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:AllerganGlobalGenericPharmaceuticalsBusinessAndCertainOtherAssetsMember 2016-08-01 2016-08-02 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2017-12-31 0001578845 agn:SettlementOfInitialAcceleratedShareRepurchaseMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-03-31 0001578845 agn:SettlementOfForwardSaleMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-03-31 0001578845 agn:OpenMarketSalesMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-12-31 0001578845 agn:SettlementOfInitialAcceleratedShareRepurchaseMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-03-31 0001578845 agn:SettlementOfForwardSaleMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-03-31 0001578845 agn:OpenMarketSalesMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-12-31 0001578845 us-gaap:AccountingStandardsUpdate201601Member agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-03-31 0001578845 us-gaap:AccountingStandardsUpdate201601Member agn:TevaPharmaceuticalIndustriesLtdMember 2018-03-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-11 2018-01-12 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-17 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-02-13 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-02-12 2018-02-13 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-05-06 2018-05-07 0001578845 2018-05-07 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:OpenMarketSalesMember 2019-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2016-12-31 0001578845 agn:OtherThanTemporaryImpairmentMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-03-31 0001578845 agn:OtherThanTemporaryImpairmentMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-09-30 0001578845 agn:SalesOfEquitySecuritiesMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-12-31 0001578845 agn:OtherFairValueMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2016-01-01 2016-12-31 0001578845 agn:OtherThanTemporaryImpairmentMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-03-31 0001578845 agn:OtherThanTemporaryImpairmentMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-09-30 0001578845 agn:SalesOfEquitySecuritiesMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:OtherFairValueMember agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 srt:MinimumMember agn:StocksOptionsMember 2019-01-01 2019-12-31 0001578845 srt:MaximumMember agn:StocksOptionsMember 2019-01-01 2019-12-31 0001578845 srt:MinimumMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001578845 srt:MaximumMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001578845 agn:TwoThousandEighteenGrantsMember 2018-01-01 2018-12-31 0001578845 agn:TwoThousandSeventeenGrantsMember 2017-01-01 2017-12-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 agn:TwoThousandNineteenGrantsMember 2019-01-01 2019-12-31 0001578845 agn:EquityBasedCompensationAwardsMember 2019-01-01 2019-12-31 0001578845 agn:EquityBasedCompensationAwardsMember 2018-01-01 2018-12-31 0001578845 agn:EquityBasedCompensationAwardsMember 2017-01-01 2017-12-31 0001578845 agn:CashSettledEquityAwardsMember agn:ZeltiqAestheticsIncMember 2017-01-01 2017-12-31 0001578845 agn:NonEquitySettledAwardsOtherMember 2017-01-01 2017-12-31 0001578845 agn:ZeltiqAestheticsIncMember 2018-01-01 2018-12-31 0001578845 agn:AllerganIncMember 2019-01-01 2019-12-31 0001578845 agn:AllerganIncMember 2018-01-01 2018-12-31 0001578845 agn:AllerganIncMember 2017-01-01 2017-12-31 0001578845 agn:ForestLaboratoriesIncMember 2017-01-01 2017-12-31 0001578845 us-gaap:RestrictedStockMember 2018-12-31 0001578845 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001578845 us-gaap:RestrictedStockMember 2019-12-31 0001578845 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001578845 agn:NonQualifiedOptionsMember 2018-12-31 0001578845 agn:NonQualifiedOptionsMember 2019-01-01 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2018-01-01 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:USEquitiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:USEquitiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:InternationalEquitiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:InternationalEquitiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:OtherEquitySecuritiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember agn:OtherEquitySecuritiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember agn:BondsAndBondFundsMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember agn:BondsAndBondFundsMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember 2019-12-31 0001578845 agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:OtherInvestmentMember agn:OtherSecuritiesMember 2019-12-31 0001578845 agn:OtherInvestmentMember agn:OtherSecuritiesMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember agn:USEquitiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember agn:USEquitiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember agn:InternationalEquitiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember agn:InternationalEquitiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember agn:OtherEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember agn:OtherEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember us-gaap:USTreasurySecuritiesMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember us-gaap:USTreasurySecuritiesMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember agn:BondsAndBondFundsMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember agn:BondsAndBondFundsMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 agn:InvestmentFundsMember us-gaap:DebtSecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member agn:OtherInvestmentMember agn:OtherSecuritiesMember 2018-12-31 0001578845 agn:OtherInvestmentMember agn:OtherSecuritiesMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001578845 us-gaap:BondsMember 2019-12-31 0001578845 us-gaap:BondsMember 2018-12-31 0001578845 us-gaap:EquitySecuritiesMember 2019-12-31 0001578845 us-gaap:EquitySecuritiesMember 2018-12-31 0001578845 agn:OtherInvestmentMember 2019-12-31 0001578845 agn:OtherInvestmentMember 2018-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember srt:ScenarioForecastMember 2020-12-31 0001578845 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember agn:AllerganIncAndForestAcquisitionsMember 2017-12-31 0001578845 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember agn:AllerganIncAndForestAcquisitionsMember 2018-01-01 2018-12-31 0001578845 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember agn:AllerganIncAndForestAcquisitionsMember 2018-12-31 0001578845 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember agn:AllerganIncAndForestAcquisitionsMember 2019-01-01 2019-12-31 0001578845 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember agn:AllerganIncAndForestAcquisitionsMember 2019-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember agn:SavingsPlanMember 2019-01-01 2019-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember agn:SavingsPlanMember 2018-01-01 2018-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember agn:SavingsPlanMember 2017-01-01 2017-12-31 0001578845 agn:TevaMember 2018-01-01 2018-12-31 0001578845 agn:TevaMember 2017-01-01 2017-12-31 0001578845 agn:DebtTenderOfferMember 2017-01-01 2017-12-31 0001578845 agn:OtherDebtTenderOfferMember 2019-01-01 2019-12-31 0001578845 agn:OtherDebtTenderOfferMember 2018-01-01 2018-12-31 0001578845 agn:OtherDebtTenderOfferMember 2017-01-01 2017-12-31 0001578845 agn:NonStrategicAssetGroupMember 2018-12-31 0001578845 agn:NonStrategicAssetGroupMember 2018-01-01 2018-12-31 0001578845 us-gaap:SeniorNotesMember 2018-01-01 2018-12-31 0001578845 agn:OtherDebtTenderOfferMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-12-31 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-01-01 2019-12-31 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-01-01 2019-12-31 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2016-08-01 2016-08-02 0001578845 agn:NaurexIncMember 2015-08-27 2015-08-28 0001578845 agn:NaurexIncMember 2017-01-01 2017-12-31 0001578845 agn:BiocellMember us-gaap:InventoryValuationReserveMember 2019-01-01 2019-12-31 0001578845 srt:MinimumMember 2019-01-01 2019-12-31 0001578845 srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:RealEstateMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 us-gaap:RealEstateMember srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:RealEstateMember 2019-12-31 0001578845 agn:FleetSubjectToOperatingLeaseMember 2019-12-31 0001578845 agn:OtherThanRealEstateAndFleetMember 2019-12-31 0001578845 us-gaap:PropertySubjectToOperatingLeaseMember 2019-01-01 2019-12-31 0001578845 agn:FleetSubjectToOperatingLeaseMember 2019-01-01 2019-12-31 0001578845 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001578845 agn:ResearchAndLaboratoryEquipmentMember 2018-12-31 0001578845 us-gaap:OtherTransportationEquipmentMember 2018-12-31 0001578845 agn:LandBuildingsAndLeaseholdImprovementsMember 2018-12-31 0001578845 us-gaap:ConstructionInProgressMember 2018-12-31 0001578845 us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0001578845 agn:ResearchAndLaboratoryEquipmentMember 2019-01-01 2019-12-31 0001578845 us-gaap:OtherTransportationEquipmentMember 2019-01-01 2019-12-31 0001578845 agn:LandBuildingsAndLeaseholdImprovementsMember 2019-01-01 2019-12-31 0001578845 us-gaap:ConstructionInProgressMember 2019-01-01 2019-12-31 0001578845 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001578845 agn:ResearchAndLaboratoryEquipmentMember 2019-12-31 0001578845 us-gaap:OtherTransportationEquipmentMember 2019-12-31 0001578845 agn:LandBuildingsAndLeaseholdImprovementsMember 2019-12-31 0001578845 us-gaap:ConstructionInProgressMember 2019-12-31 0001578845 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001578845 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001578845 2019-07-01 2019-09-30 0001578845 agn:USSpecializedTherapeuticsMember 2018-12-31 0001578845 agn:USGeneralMedicineMember 2018-12-31 0001578845 agn:InternationalMember 2018-12-31 0001578845 agn:USSpecializedTherapeuticsMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-12-31 0001578845 agn:InternationalMember 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-01-01 2019-09-30 agn:Segment 0001578845 2019-01-01 2019-09-30 0001578845 agn:USGeneralMedicineMember 2019-06-28 2019-06-30 0001578845 agn:USSpecializedTherapeuticsSegmentMember 2019-06-30 0001578845 agn:USMedicalAestheticsReportingUnitMember 2019-06-30 0001578845 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-09-30 0001578845 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-09-30 0001578845 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-12-31 0001578845 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-01-01 2019-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2018-12-31 0001578845 agn:CostBasisMember 2018-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-01-01 2019-12-31 0001578845 agn:CostBasisMember 2019-01-01 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2019-12-31 0001578845 agn:CostBasisMember 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2018-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-01-01 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2018-12-31 0001578845 agn:AccumulatedAmortizationMember 2018-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-01-01 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-01-01 2019-12-31 0001578845 agn:AccumulatedAmortizationMember 2019-01-01 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:FacialAestheticsMember 2019-01-01 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:TobiraTherapeuticsIncMember agn:GIProjectMember 2019-01-01 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0001578845 agn:GenericEntrantMember 2019-01-01 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2017-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2017-12-31 0001578845 agn:CostBasisMember 2017-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2018-01-01 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2018-01-01 2018-12-31 0001578845 agn:CostBasisMember 2018-01-01 2018-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2017-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2018-01-01 2018-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2017-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2017-12-31 0001578845 agn:AccumulatedAmortizationMember 2017-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2018-01-01 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2018-01-01 2018-12-31 0001578845 agn:AccumulatedAmortizationMember 2018-01-01 2018-12-31 0001578845 agn:CurrentlyMarketedProductMember 2018-01-01 2018-12-31 0001578845 agn:CurrentlyMarketedProductMember 2018-12-31 0001578845 agn:KybellaMember agn:NonAnnualTestingMember 2018-10-01 2018-12-31 0001578845 agn:TrueTearMember agn:NonAnnualTestingMember 2018-10-01 2018-12-31 0001578845 agn:AlmirallSAMember agn:NonAnnualTestingMember 2018-12-31 0001578845 agn:AclarisTherapeuticsIncMember agn:NonAnnualTestingMember 2018-12-31 0001578845 agn:AlmirallSAAndAclarisTherapeuticsIncMember agn:NonAnnualTestingMember 2018-01-01 2018-12-31 0001578845 agn:VitaePharmaceuticalsIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:RORytMember agn:NonAnnualTestingMember 2018-01-01 2018-03-31 0001578845 agn:AllerganIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:EyeCareProjectMember agn:ChangesInLaunchPlansMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:VitaePharmaceuticalsIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:DelayInClinicalStudiesMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:AllerganIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:DermatologyProjectMember agn:DelayInClinicalStudiesMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:AllerganIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:EyeCareProjectMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:AllerganIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CentralNervousSystemMember agn:DelayInClinicalStudiesMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:AllerganIncMember agn:IndefiniteInProcessResearchAndDevelopmentMember agn:EyeCareProjectMember agn:DelayInClinicalStudiesMember agn:AnnualTestingMember 2018-04-01 2018-06-30 0001578845 agn:ProductRightsAndOtherRelatedIntangiblesMember 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-12-31 0001578845 agn:FloatingRateNotesMember 2019-12-31 0001578845 agn:FloatingRateNotesMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember 2019-12-31 0001578845 agn:FixedRateNotesMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember 2018-12-31 0001578845 agn:OtherDebtMember 2019-12-31 0001578845 agn:OtherDebtMember 2018-12-31 0001578845 agn:CapitalLeaseMember 2018-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-01-01 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-01-01 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-01-01 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-01-01 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2018-01-01 2018-12-31 0001578845 agn:FloatingRateNotesMember agn:AbandonedInProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:AbandonedInProcessResearchAndDevelopmentMember 2018-01-01 2018-12-31 0001578845 us-gaap:SeniorNotesMember 2019-12-31 iso4217:EUR 0001578845 agn:FloatingRateNotesMember 2019-01-01 2019-12-31 0001578845 us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-12-31 0001578845 us-gaap:SeniorNotesMember 2018-12-31 0001578845 us-gaap:BorrowingsMember 2018-12-31 0001578845 agn:MarginLoanMember 2018-01-01 2018-12-31 0001578845 us-gaap:RevolvingCreditFacilityMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember us-gaap:BaseRateMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember us-gaap:BaseRateMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember us-gaap:EurodollarMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember us-gaap:EurodollarMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2017-06-13 2017-06-14 0001578845 us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-12-31 0001578845 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0001578845 country:IE 2019-01-01 2019-12-31 0001578845 country:IE 2018-01-01 2018-12-31 0001578845 country:IE 2017-01-01 2017-12-31 0001578845 us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 0001578845 us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember 2019-01-01 2019-12-31 0001578845 us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember country:BM 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember country:BM 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember country:BM 2017-01-01 2017-12-31 0001578845 us-gaap:DomesticCountryMember 2019-12-31 0001578845 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001578845 us-gaap:ForeignCountryMember 2019-12-31 0001578845 us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 0001578845 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0001578845 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0001578845 us-gaap:InternalRevenueServiceIRSMember agn:AllerganWCHoldingIncMember 2019-01-01 2019-12-31 0001578845 us-gaap:InternalRevenueServiceIRSMember agn:WarnerChilcottCorporationMember 2019-01-01 2019-12-31 0001578845 us-gaap:InternalRevenueServiceIRSMember agn:ForestLaboratoriesIncMember 2019-01-01 2019-12-31 0001578845 us-gaap:InternalRevenueServiceIRSMember agn:AllerganIncMember 2019-01-01 2019-12-31 0001578845 2019-01-29 0001578845 2018-07-30 0001578845 agn:JulyThirtyTwoThousandEighteenShareRepurchaseProgramMember 2019-12-31 0001578845 2017-09-30 0001578845 agn:SeptemberTwentyFiveTwoThousandSeventeenShareRepurchaseProgramMember 2017-12-31 0001578845 agn:SeptemberTwentyFiveTwoThousandSeventeenShareRepurchaseProgramMember 2019-12-31 0001578845 agn:MandatoryConvertiblePreferredStockMember 2015-02-28 0001578845 agn:MandatoryConvertiblePreferredStockMember 2015-02-01 2015-02-28 0001578845 agn:MandatoryConvertiblePreferredStockMember agn:AllerganIncMember 2015-02-01 2015-02-28 0001578845 2018-03-01 0001578845 us-gaap:CommonStockMember 2018-03-01 2018-03-01 0001578845 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001578845 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001578845 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0001578845 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001578845 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001578845 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001578845 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001578845 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001578845 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001578845 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001578845 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember srt:EuropeMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:AsiaPacificMiddleEastAndAfricaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:LatinAmericaAndCanadaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:OtherGeographicAreaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember srt:EuropeMember 2018-01-01 2018-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:AsiaPacificMiddleEastAndAfricaMember 2018-01-01 2018-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:LatinAmericaAndCanadaMember 2018-01-01 2018-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:OtherGeographicAreaMember 2018-01-01 2018-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember srt:EuropeMember 2017-01-01 2017-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:AsiaPacificMiddleEastAndAfricaMember 2017-01-01 2017-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:LatinAmericaAndCanadaMember 2017-01-01 2017-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember agn:OtherGeographicAreaMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:BotoxMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:BotoxMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:BotoxMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:RestasisMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:RestasisMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:RestasisMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:JuvedermCollectionMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:JuvedermCollectionMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:JuvedermCollectionMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:LumiganAndGanfortMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:LumiganAndGanfortMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:LumiganAndGanfortMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:LinzessAndConstellaMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:LinzessAndConstellaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:LinzessAndConstellaMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:BystolicAndByvalsonMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:BystolicAndByvalsonMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:BystolicAndByvalsonMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:AlphaganAndCombiganMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:AlphaganAndCombiganMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:AlphaganAndCombiganMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:LoLoestrinFeMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:LoLoestrinFeMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:BreastImplantsMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:BreastImplantsMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:BreastImplantsMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:ViibrydFetzimaMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:ViibrydFetzimaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:ViibrydFetzimaMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:EyeDropsMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:EyeDropsMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:EyeDropsMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:DelzicolAndAsacolHDMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:DelzicolAndAsacolHDMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:DelzicolAndAsacolHDMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:CoolsculptingConsumablesMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:CoolsculptingConsumablesMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:CoolsculptingConsumablesMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:AllodermMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:AllodermMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:AllodermMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:OzurdexMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:OzurdexMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:OzurdexMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:CarafateAndSulcrateMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:CarafateAndSulcrateMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:CarafateAndSulcrateMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:AczoneMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:AczoneMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:ZenpepMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:ZenpepMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:ZenpepMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:CanasaAndSalofalkMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:CanasaAndSalofalkMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:CanasaAndSalofalkMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:VraylarMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:VraylarMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:SaphrisMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:SaphrisMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:ViberziMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:ViberziMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:ViberziMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:TeflaroMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:TeflaroMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:TeflaroMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:NamzaricMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:NamzaricMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:RapafloMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:RapafloMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:RapafloMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:SkinCareMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:SkinCareMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:SkinCareMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:KybellaAndBelkyraMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:KybellaAndBelkyraMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:KybellaAndBelkyraMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:DalvanceMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:DalvanceMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:DalvanceMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:AvycazMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:AvycazMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:LilettaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:LilettaMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:NamendaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:NamendaMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:ArmourThyroidMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:ArmourThyroidMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:SavellaMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:SavellaMember 2019-01-01 2019-12-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember agn:OtherProductsRevenuesMember 2019-01-01 2019-12-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember agn:OtherProductsRevenuesMember 2019-01-01 2019-12-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember agn:OtherProductsRevenuesMember 2019-01-01 2019-12-31 0001578845 us-gaap:OperatingSegmentsMember agn:OtherProductsRevenuesMember 2019-01-01 2019-12-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-12-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-12-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-12-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:NamendaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:VraylarMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:ZenpepMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:SaphrisMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:NamzaricMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:SavellaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:AvycazMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:DalvanceMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:DalvanceMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:LilettaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OtherMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:USGeneralMedicineMember agn:OtherMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:InternationalMember agn:OtherMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001578845 srt:RestatementAdjustmentMember 2019-07-24 2019-07-24 0001578845 agn:SeveranceAndRetentionMember 2018-12-31 0001578845 us-gaap:OtherRestructuringMember 2018-12-31 0001578845 us-gaap:CostOfSalesMember agn:SeveranceAndRetentionMember 2019-01-01 2019-12-31 0001578845 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001578845 us-gaap:SellingAndMarketingExpenseMember agn:SeveranceAndRetentionMember 2019-01-01 2019-12-31 0001578845 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember agn:SeveranceAndRetentionMember 2019-01-01 2019-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001578845 agn:SeveranceAndRetentionMember 2019-01-01 2019-12-31 0001578845 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0001578845 agn:SeveranceAndRetentionMember 2019-12-31 0001578845 us-gaap:OtherRestructuringMember 2019-12-31 0001578845 agn:SeveranceAndRetentionMember 2017-12-31 0001578845 us-gaap:OtherRestructuringMember 2017-12-31 0001578845 us-gaap:CostOfSalesMember agn:SeveranceAndRetentionMember 2018-01-01 2018-12-31 0001578845 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember agn:SeveranceAndRetentionMember 2018-01-01 2018-12-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001578845 us-gaap:SellingAndMarketingExpenseMember agn:SeveranceAndRetentionMember 2018-01-01 2018-12-31 0001578845 us-gaap:SellingAndMarketingExpenseMember agn:ShareBasedCompensationMember 2018-01-01 2018-12-31 0001578845 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember agn:SeveranceAndRetentionMember 2018-01-01 2018-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember agn:ShareBasedCompensationMember 2018-01-01 2018-12-31 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001578845 agn:SeveranceAndRetentionMember 2018-01-01 2018-12-31 0001578845 agn:ShareBasedCompensationMember 2018-01-01 2018-12-31 0001578845 us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 agn:Employee 0001578845 agn:SellingAndMarketingMember 2018-01-01 2018-12-31 0001578845 us-gaap:ForwardContractsMember 2018-11-30 0001578845 2018-11-01 2018-11-30 0001578845 2018-11-30 0001578845 us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0001578845 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2019-01-31 0001578845 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-01-31 0001578845 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2019-12-31 0001578845 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 srt:MaximumMember 2018-01-01 2018-12-31 0001578845 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001578845 agn:OtherInvestmentMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001578845 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001578845 agn:OtherInvestmentMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001578845 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001578845 us-gaap:CostOfSalesMember agn:AllerganIncMember 2017-01-01 2017-12-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember agn:AllerganIncMember 2017-01-01 2017-12-31 0001578845 agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ContingentConsiderationObligationMember 2017-12-31 0001578845 agn:ContingentConsiderationObligationMember 2018-01-01 2018-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:RoyaltyReceivableMember 2018-12-31 0001578845 agn:RoyaltyReceivableMember 2019-01-01 2019-12-31 0001578845 agn:RoyaltyReceivableMember 2019-12-31 0001578845 agn:AjantaMember agn:BystolicMember 2019-01-01 2019-12-31 0001578845 agn:SandozIncorporationMember us-gaap:PendingLitigationMember 2018-08-01 2018-08-01 0001578845 agn:PrinstonMember 2019-01-01 2019-12-31 0001578845 agn:SunAndSunCertainAffiliatesMember 2019-01-01 2019-12-31 0001578845 agn:AurobindoMember 2019-01-01 2019-12-31 0001578845 agn:MylanMember 2019-01-01 2019-12-31 0001578845 agn:KBCMediaRelationsLimitedLiabilityCompanyMember agn:JuvedermMember 2019-01-01 2019-12-31 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2019-01-01 2019-12-31 agn:Trademark 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2019-12-31 0001578845 agn:LoestrinTwentyFourLitigationMember 2019-12-31 0001578845 agn:NamendaLitigationMember 2019-01-01 2019-12-31 0001578845 agn:CelexaLexaproLitigationMember 2019-01-01 2019-12-31 agn:Litigation agn:Claim 0001578845 agn:WarnerChilcottLimitedMember agn:WarnerChilcottMarketingPracticesMember 2019-01-01 2019-12-31 agn:Plaintiff 0001578845 agn:GenericDrugPricingSecuritiesLitigationMember stpr:NJ 2019-01-01 2019-12-31 agn:Defendant 0001578845 agn:PrescriptionDrugAbuseLitigationMember us-gaap:PendingLitigationMember 2019-12-31 agn:Cases 0001578845 agn:ActonelLitigationMember agn:ProductLiabilityLitigationMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:ActonelLitigationMember us-gaap:PendingLitigationMember country:CA agn:ProductLiabilityLitigationMember 2019-12-31 0001578845 agn:ActonelLitigationMember us-gaap:PendingLitigationMember agn:ProductLiabilityLitigationMember 2019-01-01 2019-12-31 0001578845 country:CA agn:ProductLiabilityLitigationMember srt:MinimumMember agn:BreastImplantLitigationMember 2019-01-01 2019-12-31 0001578845 agn:CelexaLexaproLitigationMember agn:ProductLiabilityLitigationMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:RepliFormLitigationMember agn:ProductLiabilityLitigationMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:RepliFormLitigationMember agn:ProductLiabilityLitigationMember 2019-12-31 0001578845 agn:BotoxMember 2015-12-28 2015-12-28 agn:Patent 0001578845 agn:SaintRegisMohawkTribeMember agn:RestasisMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-12-31 0001578845 agn:AllerganCapitalSarlMember 2019-12-31 0001578845 agn:AllerganFundingScsMember 2019-12-31 0001578845 agn:NonGuarantorsMember 2019-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-12-31 0001578845 srt:ConsolidationEliminationsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-12-31 0001578845 agn:AllerganCapitalSarlMember 2018-12-31 0001578845 agn:AllerganFundingScsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2018-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2018-12-31 0001578845 srt:ConsolidationEliminationsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2019-01-01 2019-12-31 0001578845 agn:AllerganCapitalSarlMember 2019-01-01 2019-12-31 0001578845 agn:AllerganFundingScsMember 2019-01-01 2019-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-01-01 2019-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-01-01 2019-12-31 0001578845 srt:ConsolidationEliminationsMember 2019-01-01 2019-12-31 0001578845 agn:NonGuarantorsMember 2018-01-01 2018-12-31 0001578845 agn:AllerganCapitalSarlMember 2018-01-01 2018-12-31 0001578845 agn:AllerganFundingScsMember 2018-01-01 2018-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2018-01-01 2018-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-01-01 2018-12-31 0001578845 srt:ConsolidationEliminationsMember 2018-01-01 2018-12-31 0001578845 agn:NonGuarantorsMember 2017-01-01 2017-12-31 0001578845 agn:AllerganFundingScsMember 2017-01-01 2017-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2017-01-01 2017-12-31 0001578845 agn:AllerganCapitalSarlMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2017-01-01 2017-12-31 0001578845 srt:ConsolidationEliminationsMember 2017-01-01 2017-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2017-12-31 0001578845 agn:AllerganCapitalSarlMember 2017-12-31 0001578845 agn:AllerganFundingScsMember 2017-12-31 0001578845 agn:NonGuarantorsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2016-12-31 0001578845 agn:AllerganCapitalSarlMember 2016-12-31 0001578845 agn:NonGuarantorsMember 2016-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-12-31 0001578845 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-12-31 0001578845 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember srt:MinimumMember 2019-01-01 2019-12-31 0001578845 agn:UnitedStatesAndCanadaMember 2019-01-01 2019-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:McKessonCorporationMember agn:UnitedStatesAndCanadaMember 2019-01-01 2019-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:McKessonCorporationMember agn:UnitedStatesAndCanadaMember 2018-01-01 2018-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:McKessonCorporationMember agn:UnitedStatesAndCanadaMember 2017-01-01 2017-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:CardinalHealthIncMember agn:UnitedStatesAndCanadaMember 2019-01-01 2019-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:CardinalHealthIncMember agn:UnitedStatesAndCanadaMember 2018-01-01 2018-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:CardinalHealthIncMember agn:UnitedStatesAndCanadaMember 2017-01-01 2017-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:AmerisourceBergenCorporationMember agn:UnitedStatesAndCanadaMember 2019-01-01 2019-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:AmerisourceBergenCorporationMember agn:UnitedStatesAndCanadaMember 2018-01-01 2018-12-31 0001578845 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember agn:AmerisourceBergenCorporationMember agn:UnitedStatesAndCanadaMember 2017-01-01 2017-12-31 agn:Customer agn:Manufacturer 0001578845 2019-10-01 2019-12-31 0001578845 2019-04-01 2019-06-30 0001578845 2019-01-01 2019-03-31 0001578845 2018-10-01 2018-12-31 0001578845 2018-07-01 2018-09-30 0001578845 2018-04-01 2018-06-30 0001578845 2018-01-01 2018-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K

 

 

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2019

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to           

 

 

Commission

File Number

 

Exact name of registrant as specified in its charter,

principal office and address and telephone number

 

State of incorporation

or organization 

 

I.R.S. Employer

Identification No. 

001-36867

 

Allergan plc

Clonshaugh Business and Technology Park

Coolock, Dublin, D17 E400, Ireland

(862) 261-7000

 

Ireland

 

98-1114402

 

 

 

 

 

 

 

001-36887

 

Warner Chilcott Limited

Victoria Place, 5th Floor

Hamilton HM 10

Bermuda

(441) 295-2244

 

Bermuda

 

98-0496358

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

 

Trading Symbol

 

Name of Each Exchange on Which Registered

Allergan plc Ordinary Shares, $0.0001 par value

 

AGN

 

New York Stock Exchange

Floating rate notes due 2020

 

AGN20A

 

New York Stock Exchange

0.500% notes due 2021

 

AGN21

 

New York Stock Exchange

1.500% notes due 2023

 

AGN 23A

 

New York Stock Exchange

1.250% notes due 2024

 

AGN 24A

 

New York Stock Exchange

2.625% notes due 2028

 

AGN28

 

New York Stock Exchange

2.125% notes due 2029

 

AGN29

 

New York Stock Exchange

 

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Allergan plc

 

Yes    

 

No    

Warner Chilcott Limited

 

Yes    

 

No    

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 

Allergan plc

 

Yes    

 

No    

Warner Chilcott Limited

 

Yes    

 

No    

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

 

Allergan plc

 

Yes    

 

No    

Warner Chilcott Limited

 

Yes    

 

No    

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Allergan plc

 

Yes    

 

No    

Warner Chilcott Limited

 

Yes    

 

No    

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

 

Allergan plc

 

 

 

Warner Chilcott Limited

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Allergan plc

Large accelerated filer

 

Accelerated filer

 

Non-accelerated filer

 

Smaller reporting company

 

Emerging growth company

 

 

 

Warner Chilcott Limited

Large accelerated filer

 

Accelerated filer

 

Non-accelerated filer

 

Smaller reporting company

 

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 

Allergan plc

 

Yes    

 

No    

Warner Chilcott Limited

 

Yes    

 

No    

 

 

The aggregate market value of the voting and non-voting stock held by non-affiliates of Allergan plc as of June 30, 2019, based upon the last sale price reported for such date on the New York Stock Exchange, was $54.8 billion. The calculation of the aggregate market value of voting and non-voting stock excludes Class A ordinary shares of Allergan plc held by executive officers, directors, and stockholders that the registrant concluded were affiliates of Allergan plc on that date.

Number of shares of Allergan plc’s Ordinary Shares outstanding on February 12, 2020: 329,002,015

This Annual Report on Form 10-K is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly owned subsidiary of Allergan plc. The information in this Annual Report on Form 10-K is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-K and, to the extent applicable, is therefore filing this form with a reduced disclosure format.

DOCUMENTS INCORPORATED BY REFERENCE

Certain information required by Part III of this Annual Report on Form 10-K (“Annual Report”) is incorporated by reference from the Allergan plc proxy statement to be filed pursuant to Regulation 14A with respect to the Registrant’s 2020 Annual General Meeting of Shareholders or, alternatively included in amendment to this Form 10-K which will be filed within 120 days of the Regisrant’s fiscal year ended December 31, 2019.

 

 

 

 


 

ALLERGAN PLC

WARNER CHILCOTT LIMITED

TABLE OF CONTENTS

FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2019

 

 

PAGE

 

PART I

ITEM 1.

Business

3

ITEM 1A.

Risk Factors

20

ITEM 1B.

Unresolved Staff Comments

43

ITEM 2.

Properties

43

ITEM 3.

Legal Proceedings

44

ITEM 4.

Mine Safety Disclosures

44

 

PART II

ITEM 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

45

ITEM 6.

Selected Financial Data

45

ITEM 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

50

ITEM 7A.

Quantitative and Qualitative Disclosures About Market Risk

80

ITEM 8.

Financial Statements and Supplementary Data

82

ITEM 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

82

ITEM 9A.

Controls and Procedures

82

ITEM 9B.

Other Information

83

 

PART III

ITEM 10.

Directors, Executive Officers and Corporate Governance

84

ITEM 11.

Executive Compensation

84

ITEM 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

84

ITEM 13.

Certain Relationships and Related Transactions, and Director Independence

84

ITEM 14.

Principal Accounting Fees and Services

84

 

PART IV

ITEM 15.

Exhibits, Financial Statement Schedules

85

ITEM 16.

Form 10-K Summary

91

 

SIGNATURES

92

 

 

 

 

 

 

2


 

PART I

 

ITEM 1.

BUSINESS

Explanatory Note

This Annual Report on Form 10-K is a combined annual report being filed separately by two registrants: Allergan plc and its indirect wholly-owned subsidiary, Warner Chilcott Limited. Each registrant hereto is filing on its own behalf all the information contained in this annual report that relates to such registrant. Each registrant hereto is not filing any information that does not relate to such registrant, and therefore makes no representations as to any such information.

Company History

Allergan plc was incorporated in Ireland on May 16, 2013 as a private limited company and re-registered effective September 20, 2013 as a public limited company.  Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, the consolidated financial statements and disclosures are for two separate registrants, Allergan plc and Warner Chilcott Limited. The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the de minimis activity between Allergan plc and Warner Chilcott Limited, references throughout this document relate to both Allergan plc and Warner Chilcott Limited. Refer to “Note 3 —Reconciliation of Warner Chilcott Limited results to Allergan plc results” in the accompanying “Notes to the Consolidated Financial Statements” in this document for a summary of the details on the differences between Allergan plc and Warner Chilcott Limited.

Allergan plc ordinary shares are traded on the NYSE under the ticker symbol “AGN.”  Pursuant to Rule 12g-3(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Allergan plc’s ordinary shares are deemed to be registered under Section 12(b) of the Exchange Act, and Allergan plc is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder.

On June 25, 2019, the Company announced that it entered into a transaction agreement (the “AbbVie Agreement”) under which AbbVie Inc. (“AbbVie”), a global, research-driven biopharmaceutical company, would acquire Allergan plc in a stock and cash transaction (the “AbbVie Transaction”), valued at $188.24 per Allergan share, or approximately $63.0 billion, based on AbbVie’s then-current stock price at the time the AbbVie Transaction was announced. At the closing of the proposed AbbVie Transaction, Company shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash for each of their existing shares. On October 14, 2019, the Company’s shareholders voted to approve the AbbVie Transaction.  The AbbVie Transaction is subject to customary regulatory approvals and other customary closing conditions.

On October 25, 2019, in connection with the AbbVie Transaction, AbbVie commenced offers to exchange all Allergan Senior Notes issued by Allergan and maturing from September 15, 2020 through March 15, 2045 for up to approximately $19.6 billion aggregate principal amount of new notes to be issued by AbbVie and cash.  In conjunction with the exchange offer, AbbVie solicited and obtained consents from eligible holders of the Allergan Senior Notes to amend each of the indentures governing the Allergan Senior Notes to eliminate substantially all of the restrictive covenants in such indentures and eliminate any guarantees of the related Allergan Senior Notes. Consummation of  the exchange offer is conditioned upon, among other things, the closing of the AbbVie Transaction.  The exchange offers are expected to close, and such amendments are expected to become operative, on or about the closing date of the AbbVie Transaction.

On January 27, 2020, in connection with the AbbVie Transaction, Allergan announced that it entered into definitive agreements to divest (a) brazikumab, an IL-23 inhibitor currently being evaluated in a phase IIb/III study as a potential treatment for Crohn’s Disease and in a phase II study for ulcerative colitis, and (b) Zenpep®, a product approved for treating exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, and Viokace®, another pancreatic enzyme preparation. These agreements were made in conjunction with the ongoing regulatory approval process for the AbbVie Transaction. AstraZeneca plc will acquire brazikumab, including global development and commercial rights.  Nestle SA will acquire Zenpep® and Viokace®.  The closing of the divestiture of brazikumab is contingent upon receipt of U.S. Federal Trade Commission and European Commission approval, the closing of the divestitures of Zenpep® and Viokace® is contingent upon receipt of of U.S. Federal Trade Commission approval, and closings of both divestitures are contingent upon the closing of the AbbVie Transaction and the satisfaction of other customary closing conditions.

References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Watson Pharmaceuticals, Inc. prior to January 23, 2013, Allergan Finance, LLC from January 23, 2013 until October 1, 2013 and Allergan plc and Warner Chilcott Limited subsequent to October 1, 2013.

References throughout to “Ordinary Shares” refer to Allergan plc’s ordinary shares, par value $0.0001 per share.

3


 

This discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, among others, those identified under “Risk Factors” in this Annual Report and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”).

Business Overview

Allergan plc is a global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.  Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.  As a part of its approach to deliver innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.  The Company has operations in more then 100 countries.  Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities.

Allergan plc’s principal executive offices are located at Clonshaugh Business and Technology Park, Coolock, Dublin, Ireland and our administrative headquarters are located at 5 Giralda Farms, Madison, NJ 07940. Our Internet website address is www.allergan.com. We do not intend this website address to be an active link or to otherwise incorporate by reference the contents of the website into this report. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and all amendments thereto, are available free of charge on our Internet website. These reports are posted on our website as soon as reasonably practicable after such reports are electronically filed with the SEC. The public may read and copy any materials that we file with the SEC electronically through the SEC website (www.sec.gov). The information contained on the SEC’s website is not incorporated by reference into this Form 10-K and should not be considered to be part of this Form 10-K. Within the Investors section of our website, we provide information concerning corporate governance, including our Corporate Governance Guidelines, Board Committee Charters and Composition, Code of Conduct and other information. Refer to “ITEM 1A. RISK FACTORS-CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS” in this document.

Business Development

2019 Business Developments

The following transaction was completed in the year ended December 31, 2019.

Acquisitions

Envy Medical, Inc.

 

On March 26, 2019, the Company acquired Envy Medical, Inc. (“Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of $81.4 million, which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities.  The transaction was treated as a business combination.  The acquisition combines Envy’s skin care product portfolio with the Company’s leading medical aesthetics business.

 

2018 Business Developments

The following are the transactions that were completed or announced in the year ended December 31, 2018.

Licenses and Asset Acquisitions

Bonti, Inc.

On October 24, 2018, the Company acquired Bonti, Inc. (“Bonti”), a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications, for $195.0 million upfront plus contingent consideration of up to $90.0 million which may be recorded if the corresponding events become probable.  The transaction was accounted for as an asset acquisition as the purchase primarily related to one asset.  The aggregate upfront expense of $196.6 million was recorded as a component of R&D expense in the year ended December 31, 2018.

4


 

Elastagen Pty Ltd

On April 6, 2018, the Company completed the acquisition of Elastagen Pty Ltd, a clinical stage medical company developing medical and cosmetic treatments including recombinant human tropoelastin, the precursor of elastin, which will be combined with Allergan's existing fillers product lines.  The transaction was accounted for as an asset acquisition as the purchase primarily related to one asset.  The aggregate upfront expense of $96.1 million was recorded as a component of R&D expense during the year ended December 31, 2018.  Under the terms of the agreement, Elastagen Pty Ltd is eligible to receive additional contingent consideration of up to $165.0 million which may be recorded if the corresponding events become probable.

Repros Therapeutics, Inc.

On January 31, 2018, the Company completed the acquisition of Repros Therapeutics, Inc., which was accounted for as an asset acquisition as the purchase primarily related to one asset.  The aggregate upfront expense of $33.2 million was recorded as a component of R&D expense during the year ended December 31, 2018.

Divestitures

Anti-Infectives Business Classified as Held for Sale

As of December 31, 2018, the Company had concluded that its Anti-Infectives business met the criteria for held for sale based on management’s intent and ability to divest the business within the next twelve months.  Assets held for sale also include miscellaneous properties.  As of June 30, 2019, as a result of the proposed AbbVie Transaction, the Company concluded that the Anti-Infectives business no longer met the criteria for held for sale.  The Anti-Infectives intangible assets and inventory were reclassified to held in use at the lower of their carrying amount before the assets were recorded as held for sale less any amortization that would have been recognized had the assets been continuously classified as held and used, or their fair value at the date of the subsequent decision not to sell.  As a result of the reclassification, the Company recorded a charge of $129.6 million, primarily related to amortization that would have been recorded if the assets were held and used, within Assets, sales and impairments, net for the nine month period the assets were held for sale.

Aclaris Therapeutics, Inc.

On November 30, 2018, the Company divested Rhofade® to Aclaris Therapeutics, Inc.  Under the terms of the agreement, the purchase price included an upfront cash payment, a potential development milestone payment for an additional dermatology product, and tiered payments based on annual net sales of Rhofade®, which had a fair value estimated to be $51.8 million as of December 31, 2019.  As a result of this transaction, the Company recorded a net loss of $266.2 million which is included as a component of “Asset sales and impairments, net” for the year ended December 31, 2018.  

Almirall, S.A.

 

On September 20, 2018, the Company completed the sale of five medical dermatology products (Aczone®, Tazorac®, Azelex®, Cordran® Tape and Seysara) in the U.S. to Almirall, S.A.  Allergan concluded that these assets constituted a business.  As part of the sale, the Company received cash consideration of $550.0 million and is eligible to receive a contingent payment of up to an additional $100.0 million in the event that net sales of the divested products in a specified calendar year exceed a sales target, to which no fair value has been ascribed.  As a result of this transaction, the Company recorded a net gain of $129.6 million included as a component of “other income / (expense), net”.

 

2017 Business Developments

The following are the transactions that were completed or announced in the year ended December 31, 2017.

Acquisitions

Keller Medical, Inc.

On June 23, 2017, the Company acquired Keller Medical, Inc. (“Keller”), a privately held medical device company and developer of the Keller Funnel® (the “Keller Acquisition”).  The Keller Acquisition combined the Keller Funnel® with the Company’s leading breast implants business.

5


 

Zeltiq® Aesthetics, Inc.

On April 28, 2017, the Company acquired Zeltiq® Aesthetics, Inc. (“Zeltiq”) for an acquisition accounting purchase price of $2,405.4 million (the “Zeltiq Acquisition”). Zeltiq was focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform (Coolsculpting®). The Zeltiq Acquisition combined Zeltiq’s body contouring business with the Company’s leading portfolio of medical aesthetics.

LifeCell Corporation

On February 1, 2017, the Company acquired LifeCell Corporation (“LifeCell”), a regenerative medicine company, for an acquisition accounting price of $2,883.1 million (the “LifeCell Acquisition”). The LifeCell Acquisition combined LifeCell's novel, regenerative medicines business, including its high-quality and durable portfolio of dermal matrix products, with the Company’s leading portfolio of medical aesthetic products, breast implants and tissue expanders. The LifeCell Acquisition expanded the Company’s medical aesthetics portfolio by adding Alloderm® and Strattice®.

Licenses and Other Transactions Accounted for as Asset Acquisitions

Lyndra, Inc.

On July 31, 2017, the Company entered into a collaboration, option and license agreement with Lyndra, Inc. (“Lyndra”) to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease and an additional, unspecified indication. The total upfront payment of $15.0 million was included as a component of R&D expense in the year ended December 31, 2017. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business.  The future option exercise payments, if any, and any future success based milestones relating to the licensed products of up to $85.0 million will be recorded if the corresponding events become probable.

Editas Medicine, Inc.

On March 14, 2017, the Company entered into a strategic alliance and option agreement with Editas Medicine, Inc. (“Editas”) for access to early stage, first-in-class eye care programs. Pursuant to the agreement, Allergan made an upfront payment of $90.0 million for the right to license up to five of Editas’ gene-editing programs in eye care, including its lead program for Leber Congenital Amaurosis (“LCA”). Under the terms of the agreement, if an option is exercised, Editas is eligible to receive contingent research and development and commercial milestones plus royalties based on net sales.  The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The total upfront payment of $90.0 million was included as a component of R&D expense in the year ended December 31, 2017.  The future option exercise payments, if any, and any future success based milestones relating to the licensed products will be recorded if the corresponding events become probable.  

In the year ended December 31, 2018, the Company exercised a $15.0 million option to develop and commercialize EDIT-101 globally for the treatment of LCA10 which was included as a component of R&D expense.  Additionally, Editas has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.  Editas received an additional $25.0 million milestone, which was included as a component as R&D expense in the year ended December 31, 2018, as the Food and Drug Administration (“FDA”) accepted the Investigational New Drug Application (“IND”) for EDIT-101.  

Assembly Biosciences, Inc.

On January 9, 2017, the Company entered into a licensing agreement with Assembly Biosciences, Inc. (“Assembly”) for the worldwide rights to Assembly’s microbiome gastrointestinal development programs.  Under the terms of the agreement, the Company made an upfront payment to Assembly of $50.0 million for the exclusive, worldwide rights to develop and commercialize certain development compounds. Additionally, Assembly will be eligible to receive success-based development and commercial milestone payments plus royalties based on net sales. The Company and Assembly will generally share development costs through proof-of-concept (“POC”) studies, and Allergan will assume all post-POC development costs.  The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business. The total upfront payment of $50.0 million was included as a component of R&D expense in the year ended December 31, 2017 and the future success based milestone payments of up to $2,771.0 million, including amounts for additional development programs not committed to as of December 31, 2017, will be recorded if the corresponding events become probable.

6


 

Lysosomal Therapeutics, Inc.

On January 9, 2017, the Company entered into a definitive agreement for the option to acquire Lysosomal Therapeutics, Inc. (“LTI”). LTI is focused on innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Under the agreement, Allergan acquired an option right directly from LTI shareholders to acquire LTI for $150.0 million plus future milestone payments following completion of a Phase Ib trial for LTI-291 as well as an upfront research and development payment. The Company concluded based on the stage of development of the assets, the lack of acquired employees and manufacturing, as well as the lack of certain other inputs and processes, that the transaction did not qualify as a business.  The aggregate upfront payment of $145.0 million was recorded as a component of R&D expense in the year ended December 31, 2017.  The Company did not exercise its option and on January 2, 2019, the option agreement with LTI was terminated.

Other Transactions

Saint Regis Mohawk Tribe

On September 8, 2017, the Company entered into an agreement with the Saint Regis Mohawk Tribe, under which the Saint Regis Mohawk Tribe obtained the rights to Orange Book-listed patents covering Restasis® (Cyclosporine Ophthalmic Emulsion) 0.05%, and the Company was granted exclusive licenses under the patents related to the product. Pursuant to the agreement, the Company paid the Saint Regis Mohawk Tribe an upfront payment of $13.8 million, which was recorded as a component of cost of sales in the year ended December 31, 2017.  

During the years ended December 31, 2019 and 2018, the Company paid royalties to the Saint Regis Mohawk Tribe of $10.1 million and $15.0 million, respectively, which were recorded within cost of sales.  As of December 31, 2019, the Company has no future royalty obligations to the Saint Regis Mohawk Tribe.

Business Description  

The Company markets brand pharmaceutical products and medical devices, including aesthetic products, under brand names through programs that are designed to generate physician and consumer loyalty. During the second quarter of 2019, the Company changed the operational and management structure for its in-development calcitonin gene-related peptide (“CGRP”) receptors, Ubrogepant and Atogepant.  These development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the Company’s management structure and reporting.  The revenues and cost of sales related to these products in prior periods were zero and any selling and marketing expenses and general and administrative expenses were de minimis, and therefore it was not necessary to recast prior periods.

As a result of the differences between the types of products we market and/or distribute, we operate and manage our business in three distinct operating segments: US Specialized Therapeutics, US General Medicine and International. The operating segments are organized as follows:

 

The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the U.S., including Medical Aesthetics, Medical Dermatology through September 20, 2018, Eye Care and Neuroscience and Urology therapeutic products.

 

The US General Medicine segment includes sales and expenses relating to branded products within the U.S. that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands.

 

The International segment includes sales and expenses relating to products sold outside the U.S.

Business Strategy

We apply four key strategies to achieve growth for our US Specialized Therapeutics, US General Medicine and International businesses: (i) internal development of differentiated and high-demand products, (ii) investing behind key marketed brands, (iii) establishment of strategic alliances and collaborations and (iv) acquisition of products and companies that complement our current business.

Based upon business conditions, our financial strength and other factors, we regularly reexamine our business strategies and may change them at any time. Refer to “ITEM 1A. RISK FACTORS —Risks Related to Our Business” in this document.

7


 

As of December 31, 2019, our portfolio of products within the US Specialized Therapeutics, US General Medicine and International segments include the following products with sales in excess of $200.0 million:

 

Product

 

Therapeutic Area

 

Active Ingredient

 

Therapeutic Classification

Alloderm®

 

Medical Aesthetics

 

Tissue

 

Skin graft

Alphagan®/Combigan®

 

Eye Care

 

Brimonidine tartrate

 

Selective alpha2 agonist

Armour Thyroid®

 

Diversified Brands

 

levothyroxine and liothyronine

 

Hypothyroidism

Botox® Cosmetics

 

Facial Aesthetics

 

Onabotulinumtoxin A

 

Acetylcholine release inhibitor

Botox® Therapeutics

 

Neuroscience and Urology

 

Botulinum toxin

 

Musculoskeletal agent

Breast Implants

 

Plastic Surgery

 

Silicone

 

Reconstructive plastic surgery

Bystolic®/Byvalson®

 

Diversified Brands

 

Nebivolol

 

Hypertension

Carafate®/Sulcrate®

 

Gastrointestinal

 

Sucralfate

 

Ulcerative colitis

Coolsculpting®

 

Medical Aesthetics

 

Medical device

 

Body contouring

Juvederm® Collection

 

Facial Aesthetics

 

Hyaluronic acid

 

Fillers

Linzess®/Constella®

 

Gastrointestinal

 

Linaclotide

 

Irritable bowel syndrome

Lo Loestrin®

 

Women's Health

 

Ethinyl estradiol and norethindrone

 

Oral contraceptive

Lumigan®/Ganfort®

 

Eye Care

 

Bimatoprost

 

Prostaglandin analogue

Ozurdex®

 

Eye Care

 

Dexamethasone

 

Intravitreal eye implant

Restasis®

 

Eye Care

 

Cyclosporine

 

Topical immunomodulator

Viibryd®/Fetzima®

 

Central Nervous System

 

Vilazodone HCl/Levomilnacipran

 

Major depressive disorders

Vraylar®

 

Central Nervous System

 

Cariprazine HCl

 

Schizophrenia, bipolar mania

Zenpep®

 

Gastrointestinal

 

Pancrelipase

 

Exocrine pancreatic insufficiency

 

Our portfolio of products also includes eye drops, including Optive and Refresh, with net sales in excess of $200.0 million in 2019.

On December 23, 2019, the Company received approval from the U.S. Food and Drug Administration (FDA) for the Company’s New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY™ is a first-in-class oral calcitonin gene-related peptide (“CGRP”) receptor antagonist (gepant) for the treatment of migraine attacks once they start.

On January 27, 2020, in connection with the AbbVie Transaction, Allergan announced that it entered into a definitive agreement to divest Zenpep® and Viokace®. This agreement was made in conjunction with the ongoing regulatory approval process for the AbbVie Transaction. The closing of the divestitures of Zenpep® and Viokace® are contingent upon receipt of U.S. Federal Trade Commission approval, closing of the AbbVie Transaction and the satisfaction of other customary closing conditions.

Businesses

Our US Specialized Therapeutics business offers certain of our branded products within the U.S., including Medical Aesthetics, Medical Dermatology through September 20, 2018, Eye Care and Neuroscience and Urology therapeutic products.

Our US General Medicine business is focused on newly developed pharmaceutical products, which are normally patented or have market exclusivity. These patented and off-patent trademarked products are branded pharmaceutical products, and as a result of patents or other market exclusivity are generally offered by a single provider when first introduced to the market. We market a number of branded products to physicians, hospitals, and other customers that we serve as well as the end patient.

Our International segment offers a wide array of branded products, including aesthetics products, outside of the United States.

8


 

Net revenues in our segments, including % of total net revenues, consisted of the following for the years ended December 31, 2019, 2018 and 2017 ($ in millions):

 

 

 

Year Ended December 31, 2019

 

 

Year Ended December 31, 2018

 

 

Year Ended December 31, 2017

 

 

 

Net Revenue

 

 

% of Total

Net Revenue

 

 

Net Revenue

 

 

% of Total

Net Revenue

 

 

Net Revenue

 

 

% of Total

Net Revenue

 

US Specialized Thera